A Quantitative Comparison of Anti-HIV Gene Therapy Delivered to Hematopoietic Stem Cells versus CD4+ T Cells

PLoS Computational Biology

Volumn 10, Issue 6, 2014, Pages

  Savkovic, Borislav ^a   Nichols, James ^a   Birkett, Donald ^b   Applegate, Tanya ^c   Ledger, Scott ^a   Symonds, Geoff ^d,e   Murray, John M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d St Vincent s Centre for Applied Medical Research   (Australia)

^e Calimmune Australia Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CELL DEATH; DISEASES; STEM CELLS; T-CELLS; VIRUSES;

ANTI-HIV; BONE MARROW; CD4 T-CELLS; CELL COUNT; CELLULAR TARGETS; CLINICAL TRIAL; HAEMATOPOIETIC STEM CELLS; HIGHLY ACTIVE ANTI-RETROVIRAL THERAPIES; QUANTITATIVE COMPARISON; THERAPY DELIVERY;

GENE THERAPY;

CD34 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; C46 HIV-1 FUSION INHIBITORY PEPTIDE; CCR5 PROTEIN, HUMAN; HYBRID PROTEIN;

APOPTOSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; DNA MODIFICATION; GENE DELIVERY SYSTEM; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; QUANTITATIVE ANALYSIS; BIOLOGICAL MODEL; BIOLOGY; COMPUTER SIMULATION; DISEASE COURSE; GENE TRANSFER; GENETICS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; VIROLOGY;

ANTIGENS, CD34; CD4-POSITIVE T-LYMPHOCYTES; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DISEASE PROGRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEMATOPOIETIC STEM CELLS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, CCR5; RECOMBINANT FUSION PROTEINS;

EID: 84903388914     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003681     Document Type: Article

References (81)

1. Cohen J, (2007) Building an HIV-proof immune system. Science 317: 612-614.
2. Deeks SG, McCune JM, (2010) Can HIV be cured with stem cell therapy? Nat Biotechnol 28: 807-810.
3. Kiem HP, Jerome KR, Deeks SG, McCune JM, (2012) Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 10: 137-147.
4. Scherer LJ, Rossi JJ, (2011) Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet 20: R100-107.
5. Symonds GP, Johnstone HA, Millington ML, Boyd MP, Burke BP, et al. (2010) The use of cell-delivered gene therapy for the treatment of HIV/AIDS. Immunol Res 48: 84-98.
6. Shafer RW, Schapiro JM, (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10: 67-84.
7. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA: the journal of the American Medical Association 308: 387-402.
8. Yeni P, (2006) Update on HAART in HIV. J Hepatol 44: S100-103.
9. von Laer D, Hasselmann S, Hasselmann K, (2006) Gene therapy for HIV infection: what does it need to make it work? J Gene Med 8: 658-667.
10. von Laer D, Hasselmann S, Hasselmann K, (2006) Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol 238: 60-77. Epub 2005 Jul 2005.
11. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, et al. (2010) Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 143: 789-801.
12. Agrawal L, Lu X, Qingwen J, VanHorn-Ali Z, Nicolescu IV, et al. (2004) Role for CCR5Delta32 protein in resistance to R5, R5×4, and ×4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol 78: 2277-2287.
13. Alkhatib G, (2009) The biology of CCR5 and CXCR4. Curr Opin HIV AIDS 4: 96-103.
14. Corbeau P, Reynes J, (2009) CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS 23: 1931-1943.
15. de Silva E, Stumpf MP, (2004) HIV and the CCR5-Delta32 resistance allele. FEMS Microbiol Lett 241: 1-12.
16. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, et al. (2011) Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117: 2791-2799.
17. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, et al. (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103: 17372-17377.
18. Macpherson JL, Boyd MP, Arndt AJ, Todd AV, Fanning GC, et al. (2005) Long-term survival and concomitant gene expression of ribozyme-transduced CD4+T-lymphocytes in HIV-infected patients. J Gene Med 7: 552-564.
19. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, et al. (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96: 785-793.
20. Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, et al. (2005) Preferential survival of CD4+T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 16: 1065-1074.
21. Ranga U, Woffendin C, Verma S, Xu L, June CH, et al. (1998) Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A 95: 1201-1206.
22. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, et al. (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4: 132ra153.
23. van Lunzen J, Glaunsinger T, Stahmer I, von Baehr V, Baum C, et al. (2007) Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Molecular therapy: the journal of the American Society of Gene Therapy 15: 1024-1033.
24. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, et al. (2014) Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. New England Journal of Medicine 370: 901-910.
25. Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, et al. (2004) Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 15: 251-262.
26. DiGiusto DL, Krishnan A, Li L, Li H, Li S, et al. (2010) RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2: 36ra43.
27. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, et al. (1999) A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94: 368-371.
28. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, et al. (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 15: 285-292.
29. Podsakoff GM, Engel BC, Carbonaro DA, Choi C, Smogorzewska EM, et al. (2005) Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Molecular therapy: the journal of the American Society of Gene Therapy 12: 77-86.
30. Kimpel J, Braun SE, Qiu G, Wong FE, Conolle M, et al. (2010) Survival of the fittest: positive selection of CD4+T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One 5: e12357.
31. ClinicalTrials.gov (2012) Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection. ClinicalTrialsgov Identifier: NCT01734850 Available online under: http://clinicaltrials.gov/ct2/show/NCT01734850.
32. Holt N, Wang J, Kim K, Friedman G, Wang X, et al. (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28: 839-847.
33. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, et al. (2008) Establishment of HIV-1 resistance in CD4+T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816.
34. Ando D, Tebas P, Stein D, Wang S, Lee G, et al. (2011) HAART Treatment Interruption Following Adoptive Transfer of Zinc Finger Nuclease (ZFN) CCR5 Modified AutologousCD4 T-cells (SB-728-T) to HIV-infected Subjects Demonstrates Durable Engraftment and Suppression of Viral Load 51th ICAAC, Chicago, IL, September 17-20, 2011.
35. June CH, Tebas P, Stein D, Mitsuyasu R, Lalezari J, et al. (2012) Induction of Acquired CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) Correlates with Increases in CD4 Count and Effects on Viral Load in HIV-infected Subjects. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, Washington, United States. CROI 2012.
36. Mitsuyasu R, Lalezari J, Deeks S, Wang S, Lee G, et al. (2011) Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified Autologous CD4 T-cells (SB-728-T) to Aviremic HIV-infected Subjects with Suboptimal CD4 Counts (200-500 cells/mm3) [Abstract H1-375]. In: Proceedings of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September, 2011; Chicago, Illinois, United States. 51st ICAAC.
37. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AIM, et al. (2008) Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection. New England Journal of Medicine 359: 1442-U1446.
38. Westby M, van der Ryst E, (2010) CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antiviral chemistry & chemotherapy 20: 179-192.
39. Wolinsky SM, Veazey RS, Kunstman KJ, Klasse PJ, Dufour J, et al. (2004) Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and ×4 primate immunodeficiency viruses. Virology 328: 19-29.
40. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, et al. (1993) Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118: 681-688.
41. Nishimura Y, Brown CR, Mattapallil JJ, Igarashi T, Buckler-White A, et al. (2005) Resting naive CD4+T cells are massively infected and eliminated by ×4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci U S A 102: 8000-8005.
42. Shepherd JC, Jacobson LP, Qiao W, Jamieson BD, Phair JP, et al. (2008) Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 198: 1104-1112.
43. Murray JM, Fanning GC, Macpherson JL, Evans LA, Pond SM, et al. (2009) Mathematical modelling of the impact of haematopoietic stem cell-delivered gene therapy for HIV. J Gene Med 11: 1077-1086.
44. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, et al. (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 15: 285-292.
45. Bonyhadi ML, Rabin L, Salimi S, Brown DA, Kosek J, et al. (1993) HIV induces thymus depletion in vivo. Nature 363: 728-732.
46. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+T-cell changes independent of viral load. Blood 104: 942-947.
47. Murray JM, Kaufmann G, Kelleher AD, Cooper DA, (1998) A model of primary HIV-1 infection. Math Biosci 154: 57-85.
48. Essunger P, Perelson AS, (1994) Modeling HIV infection of CD4+T-cell subpopulations. J Theor Biol 170: 367-391.
49. Tebit DM, Nankya I, Arts EJ, Gao Y, (2007) HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? AIDS Rev 9: 75-87.
50. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, et al. (2005) Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 79: 9006-9018.
51. Marconi VC, Grandits G, Okulicz JF, Wortmann G, Ganesan A, et al. (2011) Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS. PLoS One 6: e17956.
52. Ribeiro RM, Hazenberg MD, Perelson AS, Davenport MP, (2006) Naive and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol 80: 802-809.
53. Weinberger AD, Perelson AS, Ribeiro RM, Weinberger LS, (2009) Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection. PLoS Comput Biol 5: e1000467.
54. Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, et al. (2012) Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. J Infect Dis 205: 174-184.
55. Savkovic B, Macpherson JL, Zaunders J, Kelleher AD, Knop AE, et al. (2012) T-lymphocyte perturbation following large-scale apheresis and hematopoietic stem cell transplantation in HIV-infected individuals. Clin Immunol 144: 159-171.
56. Zaunders J, Carr A, McNally L, Penny R, Cooper DA, (1995) Effects of primary HIV-1 infection on subsets of CD4+ and CD8+T lymphocytes. AIDS 9: 561-566.
57. Huenecke S, Behl M, Fadler C, Zimmermann SY, Bochennek K, et al. (2008) Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis. Eur J Haematol 80: 532-539.
58. Pantaleo G, Graziosi C, Fauci AS, (1993) New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328: 327-335.
59. Ledger S, Savkovic B, Murray J, Symonds G. (2012) Short-hairpin RNA to CCR5 and its effect on HIV susceptible cultures through the use of a lentiviral vector. In: Proceedings of the 24th Annual Conference of the Australasian Society for HIV Medicine 17-19 October, 2012 Melbourne, Victoria, Australia. ASHM 2012.
60. Zahn RC, Hermann FG, Kim EY, Rett MD, Wolinsky SM, et al. (2008) Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gene Therapy 15: 1210-1222.
61. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, et al. (2004) Inhibition of Human Immunodeficiency Virus Type 1 Entry in Cells Expressing gp41-Derived Peptides. Journal of Virology 78: 568-575.
62. Alexander L, Zhang S, McAuliffe B, Connors D, Zhou N, et al. (2009) Inhibition of envelope-mediated CD4+T-cell depletion by human immunodeficiency virus attachment inhibitors. Antimicrob Agents Chemother 53: 4726-4732.
63. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, et al. (1995) Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1: 129-134.
64. Holm GH, Gabuzda D, (2005) Distinct mechanisms of CD4+ and CD8+T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J Virol 79: 6299-6311.
65. Holm GH, Zhang C, Gorry PR, Peden K, Schols D, et al. (2004) Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J Virol 78: 4541-4551.
66. Joshi A, Nyakeriga AM, Ravi R, Garg H, (2011) HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity. J Biol Chem 286: 36404-36413.
67. Applegate TL, Birkett DJ, McIntyre GJ, Jaramillo AB, Symonds G, et al. (2010) In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy. Retrovirology 7: 83.
68. Aviran S, Shah PS, Schaffer DV, Arkin AP, (2010) Computational models of HIV-1 resistance to gene therapy elucidate therapy design principles. PLoS Comput Biol 6: e1000883.
69. Lund O, Lund OS, Gram G, Nielsen SD, Schonning K, et al. (1997) Gene therapy of T helper cells in HIV infection: mathematical model of the criteria for clinical effect. Bull Math Biol 59: 725-745.
70. Murray JM, Kaufmann GR, Hodgkin PD, Lewin SR, Kelleher AD, et al. (2003) Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. Immunol Cell Biol 81: 487-495.
71. Jenkins M, Hanley MB, Moreno MB, Wieder E, McCune JM, (1998) Human immunodeficiency virus-1 infection interrupts thymopoiesis and multilineage hematopoiesis in vivo. Blood 91: 2672-2678.
72. Cohen Stuart J, Hamann D, Borleffs J, Roos M, Miedema F, et al. (2002) Reconstitution of naive T cells during antiretroviral treatment of HIV- infected adults is dependent on age. Aids 16: 2263-2266.
73. Mitsuyasu RT, Zack JA, Macpherson JL, Symonds GP, (2011) Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt. Stem cells international 2011: 393698.
74. Walker JE, Chen RX, McGee J, Nacey C, Pollard RB, et al. (2012) Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol 86: 5719-5729.
75. Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, et al. (2013) Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood 121: 1524-1533.
76. McLean AR, Michie CA, (1995) In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci U S A 92: 3707-3711.
77. Younan PM, Polacino P, Kowalski JP, Peterson CW, Maurice NJ, et al. (2013) Positive selection of mC46-expressing CD4+T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 122: 179-187.
78. Doitsh G, Galloway NLK, Geng X, Yang Z, Monroe KM, et al. (2014) Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505: 509-514.
79. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, et al. (2014) IFI16 DNA Sensor Is Required for Death of Lymphoid CD4 T Cells Abortively Infected with HIV. Science 343: 428-432.
80. Savkovic B, Symonds G, Murray JM, (2012) Stochastic Model of In-Vivo ×4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc. PLoS One 7: e38755.
81. Carter CC, McNamara LA, Onafuwa-Nuga A, Shackleton M, Riddell Jt, et al. (2011) HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 9: 223-234.